Search
Showing results for "1"
Embrace the potential of children with Rett Syndrome by exploring how to plan opportunities for uptime, maximizing their engagement and participation in meaningful activities.
Research
Long-term survival for infants born with orofacial clefts in Western AustraliaParents with a child diagnosed with an OFC ± additional minor anomalies only can be reassured that the OFC does not influence survival rates in infancy
Research
Dynamic molecular changes during the first week of human life follow a robust developmental trajectorySystems biology and innovative data integration can provide fresh insights into the molecular ontogeny of the first week of life
Research
Cost-effectiveness analysis of routine screening using massively parallel sequencing for maturity-onset diabetes of the young in a pediatric diabetes cohortRoutine MPS screening for Maturity-onset diabetes of the young in the pediatric population with diabetes could reduce health system costs and improve patient QoL
News & Events
Introducing the Rio Tinto Children's Diabetes Centre, A JDRF Global Centre of ExcellenceIntroducing the Rio Tinto Children's Diabetes Centre: A JDRF Global Centre of Excellence
News & Events
Montanna's diabetes dashA diabetes diagnosis is a shock at any time but spare a thought for the Rustens who jumped on a plane to Perth from Kununurra within an hour of diagnosis.
Research
Genome-wide association study of autistic-like traits in a general population study of young adultsResearch has proposed that autistic-like traits in the general population lie on a continuum, with clinical ASD representing the extreme end of this...
Research
“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trialsEach year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.
The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.
Research
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic LeukemiaKMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.